10-Q: Acrivon Therapeutics Reports Positive Clinical Data, Extends Runway

Acrivon Therapeutics, Inc. reported positive clinical data for its lead drug candidates ACR-368 and ACR-2316, while extending its cash runway into Q2 2027 despite continued operating losses.

Summary

• Acrivon Therapeutics, a clinical-stage biotechnology company, is advancing its precision medicine pipeline in oncology using its proprietary AP3 platform.
• The company's lead candidate, ACR-368, is in a potentially registrational Phase 2 trial for endometrial cancer, having received FDA Fast Track and Breakthrough Device designations.
• Positive clinical data from the Phase 2 trial of ACR-368 in recurrent endometrial cancer patients showed a 35% confirmed overall response rate (ORR) and 80% tumor shrinkage in OncoSignature-positive patients.
• A Phase 2 single-arm trial of ACR-368 with ULDG sensitization in biomarker unselected 2nd line endometrial cancer patients was initiated in July 2025, showing a confirmed ORR of approximately 13% in heavily pretreated BMpatients.
• ACR-2316, a novel WEE1/PKMYT1 inhibitor, is in Phase 1 studies, with initial clinical activity including tumor shrinkage and a confirmed partial response observed at Dose Level 3.
• The company reported a net loss of $58.9 million for the nine months ended September 30, 2025, compared to $57.7 million for the same period in 2024.
• Research and development expenses were $45.2 million for the nine months ended September 30, 2025, a slight decrease from $45.4 million in the prior year, primarily due to reduced ACR-368 milestone costs offset by increased ACR-2316 development.
• As of September 30, 2025, cash, cash equivalents, and investments totaled $134.4 million, providing a projected cash runway into the second quarter of 2027.
• The company obtained unencumbered world-wide exclusive rights for ACR-368 in July 2025, following the expiration of Lilly's limited right of first negotiation.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong clinical trial results for both lead candidates and strategic advancements like securing full rights to ACR-368. However, this is tempered by continued significant operating losses and the explicit need for future capital raises, which are typical for a clinical-stage biotech but still represent financial challenges.

Positives

• ACR-368 demonstrated a 35% confirmed overall response rate and 80% tumor shrinkage in OncoSignature-positive endometrial cancer patients in a registrational-intent Phase 2 trial.
• ACR-368 received FDA Fast Track designation for monotherapy and Breakthrough Device designation for its OncoSignature assay, highlighting its potential for effective treatment.
• Initial clinical activity, including tumor shrinkage and a confirmed partial response, was observed for ACR-2316 in its Phase 1 study at a dose level below the projected recommended Phase 2 dose.
• The company secured unencumbered world-wide exclusive rights for ACR-368 in July 2025, enhancing strategic flexibility for partnerships and commercialization.
• Existing cash, cash equivalents, and investments of $134.4 million are projected to fund operations into the second quarter of 2027, providing a reasonable financial runway.

Negatives

• Net loss increased to $58.9 million for the nine months ended September 30, 2025, compared to $57.7 million for the same period in 2024, indicating continued unprofitability.
• The company has an accumulated deficit of $255.9 million as of September 30, 2025, reflecting significant historical losses.
• Operating cash burn remains high, with $48.4 million used in operating activities for the nine months ended September 30, 2025.
• The company will require substantial additional funding beyond Q2 2027 to support its planned operating activities and growth strategy.

Risks

• The company has incurred significant losses since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future, potentially never achieving or maintaining profitability.
• Additional funding will be required to meet financial obligations and pursue business objectives; if unable to raise capital when needed, the company may be forced to curtail planned longer-term operations and growth strategy.
• Sales of a substantial number of currently restricted shares in the public market could occur, potentially causing the market price of common stock to drop significantly.
• Disruptions at the FDA, SEC, and other government agencies (e.g., government shutdowns) could hinder their ability to perform normal business functions, negatively impacting the company's business and regulatory processes.

Future Outlook

The company anticipates continued significant operating losses for the foreseeable future as it expands research and development efforts, advances drug candidates through clinical development, seeks regulatory approvals, and potentially commercializes approved drugs. It expects to need substantial additional funding beyond the second quarter of 2027 to support its planned operating activities and growth strategy. A development candidate nomination for a preclinical program is anticipated in 2025, and a clinical data update for ACR-2316 is expected in the second half of 2025. The company plans to conduct additional preclinical and clinical evaluations to assess ACR-368's synergistic potential with other chemotherapeutic agents.

Management Comments

• We remain confident in our strategy for ACR-368 in endometrial cancer based on emerging clinical data, competitive positioning given limited treatment options, and the strong commercial opportunity in both secondand front-line settings.
• The ACR-368 OncoSignature accurately identified patients whose tumors are sensitive to ACR-368, with 80% of BM+ patients demonstrating tumor shrinkage.
• Overall, we observed significant anti-tumor activity and disease control in BM+ patients with aggressive, refractory tumors that did not respond at all (0% ORR) to the last line of prior therapy, and with a confirmed ORR more than double (35%) the best ORR observed in the last prior line of therapy (15%) for all BM+ patients.
• Based on the totality of the preclinical and observed clinical data, we believe this supports significant ULDG sensitization to ACR-368 in BMpatients.
• We anticipate providing a clinical data update for ACR-2316 in the second half of 2025.
• We believe that our existing cash, cash equivalents and investments as of September 30, 2025, will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2027.

Industry Context

Acrivon Therapeutics operates in the highly competitive and rapidly evolving precision oncology sector, focusing on small molecule inhibitors and companion diagnostics. Its AP3 platform aims to overcome limitations of genetics-based precision medicine by interpreting drug-regulated pathway activity. The positive clinical data for ACR-368 in endometrial cancer, a tumor type with limited treatment options, positions it favorably. The development of ACR-2316 as a WEE1/PKMYT1 inhibitor also aligns with industry trends towards targeted therapies. The company's strategy to identify patient responders through its OncoSignature assay is consistent with the broader industry shift towards personalized medicine, aiming to improve efficacy and reduce adverse effects.

Comparison to Industry Standards

• The 35% confirmed ORR for ACR-368 in OncoSignature-positive endometrial cancer patients, particularly in heavily pre-treated and refractory populations, appears promising when compared to typical response rates for late-line therapies in aggressive cancers. For instance, in similar patient populations, ORRs for standard-of-care or other investigational agents can often be in the low double-digits or single-digits.
• The 50% ORR in relapsed BM+ patients and 33% ORR in refractory BM+ patients with ACR-368 monotherapy are notable, especially given that refractory patients had 0% ORR to their last prior line of therapy. This suggests a significant improvement over previous treatments for these difficult-to-treat patients.
• The rapid advancement of ACR-2316 from lead identification to first patient dosing in a Phase 1 trial within 15 months, guided by the AP3 platform, demonstrates efficient drug development, which is a competitive advantage in the biotech industry.
• The observed significant drug target engagement for ACR-2316 at Dose Level 1 and initial clinical activity at Dose Level 3 (below projected RP2D) are positive indicators for a Phase 1 trial, suggesting a favorable therapeutic window and potential for further dose escalation and efficacy.

Corporate Governance

Legal Proceedings

• The company is not currently party to any material legal proceedings and is not aware of any pending or threatened legal proceedings that could have an adverse effect on its business, operating results, or financial condition.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises (equity offerings, ATM program) and exercise of pre-funded warrants. Positive clinical data could increase share value, but continued losses and funding needs pose risks.
• Employees: Stock-based compensation plans (2022 Plan, 2022 ESPP, Inducement Plan) are in place, and personnel-related R&D costs increased due to headcount and salaries, indicating continued investment in human capital. The Inducement Plan amendment supports attracting new talent.
• Customers (future patients): Positive clinical data for ACR-368 and ACR-2316, along with FDA designations, suggest potential for new, more effective treatment options for various cancers, particularly endometrial cancer.
• Creditors: The company's significant accumulated deficit and recurring losses indicate reliance on external funding, which could impact creditworthiness, though the current cash runway provides stability for the near term.
• Partners (Lilly, Akoya): The expiration of Lilly's ROFN for ACR-368 provides Acrivon with greater flexibility in strategic partnerships. Continued collaboration with Akoya for the OncoSignature test is ongoing.

Next Steps

• Advance ACR-368 in its potentially registrational Phase 2 trial for endometrial cancer.
• Continue to explore the combination of ACR-368 with ULDG in the ongoing endometrial cancer trial.
• Conduct additional preclinical and clinical evaluations to assess ACR-368's synergistic potential with other chemotherapeutic agents, particularly topoisomerase inhibitors in ADCs.
• Continue advancing ACR-2316 in Phase 1 studies, with a clinical data update anticipated in the second half of 2025.
• Nominate a development candidate for the preclinical program directed against an undisclosed cell cycle regulatory target in 2025.
• Evaluate the impact of the new U.S. tax legislation (One Big Beautiful Bill Act or OBBBA) on operations and financial statements.
• Raise additional capital through equity offerings, debt financings, collaborations, or other arrangements to fund operations beyond Q2 2027.

Key Dates

Recommendation

Acrivon Therapeutics presents a mixed but typical picture for a clinical-stage biotech. The positive clinical data for ACR-368 in endometrial cancer, including high ORR and tumor shrinkage in a difficult-to-treat population, along with FDA Fast Track and Breakthrough Device designations, are significant catalysts. The early clinical activity for ACR-2316 is also encouraging. The company has extended its cash runway into Q2 2027, providing near-term stability. However, the company continues to incur substantial operating losses and will require significant additional funding beyond this period. While the clinical progress is strong and the AP3 platform shows promise, the inherent risks of drug development, regulatory hurdles, and future dilution from capital raises warrant a 'Hold' recommendation. Investors should monitor upcoming clinical data updates and the company's ability to secure future financing.

Keywords

Acrivon Therapeutics, ACRV, Oncology, Precision Medicine, AP3 Platform, ACR-368, Prexasertib, Endometrial Cancer, Phase 2 Clinical Trial, OncoSignature Assay, Fast Track Designation, Breakthrough Device Designation, ACR-2316, WEE1/PKMYT1 Inhibitor, Phase 1 Clinical Trial, Biotechnology, Drug Development, SEC Filing, 10-Q